BALTIMORE--()--The biopharmaceutical company Oncomatrix has developed and clinically validated a new immunohistochemistry-based kit to diagnose and prognose the invasiveness of different tumors, such as pancreas, breast, lung, colon and head & neck: DMTXinvaScan.
A large multicenter clinical trial has shown sensitivity and specificity levels higher than 90%.
Oncomatrix has identified a number of genes and proteins that are differentially expressed in tumor-associated stroma mesenchymal cells and extracellular matrix. The gen collagen XI-α1, and its encoded protein, are expressed in the stroma fibroblasts that are associated to invasive tumors, but not in those fibroblasts that are associated to non-invasive tumors or to benign lesions or inflammatory processes.
Oncomatrix has developed and clinically validated a monoclonal antibody that detects collagen XI-α1. This antibody is the main component of DMTXinvaScan, the Oncomatrix kit that enables an accurate diagnosis and prognosis of invasive tumors, facilitating the selection of patient cancer treatment.
DMTXinvaScan will be presented this week at the United States and Canadian Academy of Pathology USCAP meeting in Baltimore, USA, by Oncomatrix and their clinical and scientific collaborators from the Hospital Universitario Marques de Valdecilla in Spain.
Oncomatrix is focused on the development of personalized biological treatments, to fight against invasive tumors. The company is based in the Bizkaia Technology Park, in the Basque Country, Spain.
Oncomatrix scientists have discovered new genes, proteins and mechanisms in the tumor-associated stroma cells and extracellular matrix, which trigger tumor invasiveness.
Oncomatrix carries out the development of Diagnostic devices and Antibody-Drug Conjugates and Immunotoxins against these novel targets, in collaboration with reference research centers, universities and hospitals in Europe and USA, such as National Jewish Health, Case Western Reserve University, University of Stuttgart, Hospital Universitario Marqués de Valdecilla and Hospital Central de Asturias.